Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) PT at $79.31

Tempus AI, Inc. (NASDAQ:TEM) has earned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $78.1538.

TEM has been the subject of several research reports. Piper Sandler cut their price objective on Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Robert W. Baird assumed coverage on Tempus AI in a research report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective for the company. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Morgan Stanley cut their price target on Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, Stifel Nicolaus set a $60.00 target price on Tempus AI in a report on Wednesday, February 25th.

Insider Transactions at Tempus AI

In related news, CEO Ryan Fukushima sold 9,592 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $566,407.60. Following the completion of the sale, the chief executive officer directly owned 694,354 shares of the company’s stock, valued at $41,001,603.70. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James William Rogers sold 19,966 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $73.20, for a total value of $1,461,511.20. Following the transaction, the chief financial officer directly owned 111,250 shares in the company, valued at approximately $8,143,500. The trade was a 15.22% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 590,109 shares of company stock worth $37,056,566. Insiders own 26.27% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Capital LLC grew its position in Tempus AI by 26.9% in the 3rd quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock valued at $6,793,000 after buying an additional 17,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Tempus AI by 1,459.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock worth $8,174,000 after acquiring an additional 94,783 shares during the period. Hussman Strategic Advisors Inc. purchased a new stake in shares of Tempus AI in the third quarter valued at about $1,695,000. Vanguard Group Inc. increased its stake in shares of Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after acquiring an additional 1,706,837 shares during the period. Finally, Krane Funds Advisors LLC raised its holdings in Tempus AI by 218.2% during the third quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock worth $2,427,000 after purchasing an additional 19,358 shares in the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Price Performance

Shares of TEM opened at $53.05 on Friday. Tempus AI has a 1-year low of $36.22 and a 1-year high of $104.32. The firm has a market capitalization of $9.44 billion, a PE ratio of -37.62 and a beta of 5.29. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The company’s fifty day moving average price is $60.35 and its 200-day moving average price is $72.78.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.